1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
April 2025 in “Journal of Dermatology for Physician Assistants” Vitiligo and alopecia should be covered by Medicaid and TRICARE as medical, not cosmetic, conditions.
February 2025 in “Expert Opinion on Drug Metabolism & Toxicology” Future alopecia treatments will improve with targeted therapies and personalized approaches.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
February 2024 in “Veterinary sciences” Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.
September 2025 in “Value in Health”
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
16 citations
,
January 2021 in “BMC Genomics” Higher hair follicle density leads to more wool in rabbits, influenced by specific genes and lncRNAs.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
1 citations
,
May 2025 in “Journal of Cosmetic Dermatology” Blood metabolites significantly influence alopecia areata risk.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
January 2024 in “Acta dermato-venereologica”
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
October 2024 in “JEADV Clinical Practice” UK dermatologists commonly use corticosteroids and minoxidil to treat hair loss conditions.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
Vitamin D3 helps treat mild to moderate alopecia areata, especially when combined with other treatments.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.